Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT5BFT0)

DTT Name	Interleukin-1 receptor (IL1R)
Gene Name	IL1R1
DTT Type	Clinical trial target	[1]
UniProt ID	IL1R1_HUMAN ; IL1R2_HUMAN
TTD ID	T90835
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
KEGG Pathway	MAPK signaling pathway (hsa04010 ) Cytokine-cytokine receptor interaction (hsa04060 ) NF-kappa B signaling pathway (hsa04064 ) Osteoclast differentiation (hsa04380 ) Hematopoietic cell lineage (hsa04640 ) Th17 cell differentiation (hsa04659 ) Inflammatory mediator regulation of TRP channels (hsa04750 ) Pathogenic Escherichia coli infection (hsa05130 ) Shigellosis (hsa05131 ) Amoebiasis (hsa05146 ) Human cytomegalovirus infection (hsa05163 ) Human T-cell leukemia virus 1 infection (hsa05166 ) Fluid shear stress and atherosclerosis (hsa05418 )
Reactome Pathway	Interleukin-1 signaling (R-HSA-9020702 ) Potential therapeutics for SARS (R-HSA-9679191 ) Interleukin-10 signaling (R-HSA-6783783 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isunakinra	DMA41DO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

References

1	Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2017 Sep;43(5):287-296.